Elevance Health (NYSE:ELV) Shows Strong Financial Performance and Executive Confidence

• Executive Confidence: Elevance Health's CEO acquired shares, signaling a positive internal outlook.
• Strong Q2 Financials: The company surpassed analyst expectations for both adjusted earnings per share and revenue.
• Upgraded Full-Year Guidance: Elevance Health raised its fiscal 2026 adjusted earnings and operating cash flow forecasts.

Elevance Health, Inc. (NYSE:ELV) is the second-largest health insurer in the United States, trailing only UnitedHealth Group. Elevance Health operates the Anthem brand Blue Cross and Blue Shield plans across 14 states. It also manages state Medicaid contracts and is expanding its Carelon healthcare services business.

On July 17, 2026, President and CEO Gail Boudreaux demonstrated executive confidence in Elevance Health by acquiring 680 shares of Common Stock. The shares were purchased at a price of $366.41 each. This insider buying transaction increased her total ownership in Elevance Health to 169,931 shares, signaling a positive internal outlook.

This executive confidence aligns with Elevance Health's strong financial performance. Elevance Health announced impressive second-quarter results, with adjusted earnings of $7.45 per share, which was well above the analyst estimate of $6.21. Revenue also surpassed expectations, coming in at $49.83 billion against a forecast of $48.69 billion.

Following these results, Elevance Health raised its fiscal year guidance. The company now projects fiscal 2026 adjusted earnings of at least $27.00 per share. It also increased its operating cash flow forecast to at least $6.00 billion. Operating cash flow is the cash a company generates from its regular business activities.

The improved outlook is driven by reduced medical costs and strong operating results, as highlighted by Forbes. The WSJ also reported on the raised earnings outlook, noting it follows a period of higher sales for the health insurer. This positive financial news caused shares to rise 1.8% to $397.20 in pre-market trading.